Metagenomi Files Q1 2025 10-Q, Details R&D and Agreements
Ticker: MGX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1785279
| Field | Detail |
|---|---|
| Company | Metagenomi, Inc. (MGX) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, R&D expenses, licensing agreement
TL;DR
Metagenomi's Q1 2025 10-Q shows R&D spend and an ongoing deal with Affini-T Therapeutics.
AI Summary
Metagenomi, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses and general and administrative expenses for the first quarter of 2025. The filing also references a Development Option and License Agreement with Affini-T Therapeutics, Inc., with terms extending to January 1, 2030.
Why It Matters
This filing provides insight into Metagenomi's operational expenses and ongoing strategic partnerships, crucial for understanding its financial health and future development trajectory.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which is inherently high-risk due to long development cycles and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Covers the first quarter of 2025)
- 2025-01-01 — Start of Reporting Period (Beginning of the first quarter of 2025)
Key Players & Entities
- Metagenomi, Inc. (company) — Filer of the 10-Q
- Affini-T Therapeutics, Inc. (company) — Party to a Development Option and License Agreement
- 20250331 (date) — End of reporting period
- 20250513 (date) — Filing date
FAQ
What were Metagenomi's research and development expenses for the first quarter of 2025?
The filing indicates that 'us-gaap:ResearchAndDevelopmentExpenseMember' was reported for the period '2025-01-01' to '2025-03-31'.
What is the nature of the agreement between Metagenomi and Affini-T Therapeutics, Inc.?
The filing references a 'mgx:DevelopmentOptionAndLicenseAgreementMember' involving 'mgx:AffiniTTherapeuticsIncMember'.
When does the Development Option and License Agreement with Affini-T Therapeutics, Inc. expire?
The agreement has terms extending to '2030-01-01'.
What was the filing date for this 10-Q report?
The 10-Q report was filed on '20250513'.
What is Metagenomi's primary business classification?
Metagenomi, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Metagenomi, Inc. (MGX).